GILEAD SCIENCES revenue breakdown overview

GILEAD SCIENCES revenue for the last year amounted to 26.11 B CHF, the most of which — 17.81 B CHF — came from its highest performing source at the moment, Human Immunodeficiency Virus, the year earlier bringing 15.30 B CHF. The greatest contribution to the revenue figure was made by United States — last year it brought GILEAD SCIENCES 18.70 B CHF, and the year before that — 16.37 B CHF.